Intellia Therapeutics shares fall 4.12% premarket ahead of Q2 2025 earnings call.

Intellia Therapeutics, Inc. fell 4.12% in premarket trading, with the company scheduled to hold a conference call on August 7, 2025, to discuss its second quarter 2025 financial results and operational highlights. The call is expected to provide insights into the company's performance and future outlook, which may have contributed to the stock's decline as investors anticipate potential challenges or underperformance.